Lysophosphatidylethanolamine 16:0

lipid

Lysophosphatidylethanolamine 16:0 is enriched in lipid-rich noncalcified plaque, marking high-risk atherogenic lesions susceptible to rupture.

Pathway placement

Cascade stepLipid retention & oxidation

Confidencehigh

RationaleLipid biomarker of lipid-rich noncalcified plaque; hallmark of rupture-prone atherosclerotic lesions.

Druggability

Not assessed (no mapped human gene target).

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma (EDTA to limit oxidation)

Collection tube

K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)

Method / principle

LC-MS/MS lipidomics (targeted or shotgun)

Reagent / substrate

Deuterated lipid-class internal standards; MS/MS transitions

Platform

LC-MS/MS

Turnaround · availability

Research · Research-only

Variability of the Plasma Lipidome and Subclinical Coronary Atherosclerosis.
Arteriosclerosis, thrombosis, and vascular biology · 2021 · PMID 34809445 · doi